The Efficacy Of Temozolomide And Nimotuzumab Combined With Postoperative Chemoradiation Therapy In The Treatment Of Glioma

Glioma, which was first proposed in 1983, is a kind of nerve or interstitial substance, origined from neural ectoderm. Glioma is due to the abnormal proliferation of glial cells differentiation, resulting in intracranial disorders, placeholder and epilepsy and clinical manifestation of primary intracranial tumor. It is also one of the highest percentages of intracranial tumors. According to the site of the tumor, morphology, molecular biological characteristic, genetic change and other factors, glioma could be divided into 4 levels. As the high recurrence and death rate in the process of chemotherapy, glioma is one of the major diseases threatening human health. Surgery is still the main method for the treatment of glioma, it can relieve the pain and prolong life of the patients by surgical removal of the lesions. Main aim of the traditional surgery is to narrow lesions, relieve intracranial placeholder, and reduce the incidence of brain functional areas appear local disturbance. In addition, surgery can strive for more time for biomarker detection and chemoradition therapy. Many common cytotoxic drugs have applied in glioma chemotherapy, including common nitrosoureas and other kinds of alkylating agent. The postoperative adjuvant treatment by chemotherapy in patients with glioma has become the common method. We can’t completely kill glioma cells by increasing the radiation dose in the process of adjuvant therapy. Although in the use of functional magnetic resonance and microscope, the removal of tumor tissue can only do under the microscope. In addition, it is difficult to remove glioma completely due to the glioma cells invasion. Surgical treatment can also lead to upgrade pathogenesis of glioma, from stationary phase to breeding period, increasing the recurrence of glioma. In the field of the treatment of glioma, the further explore space of the way of surgery and chemoradition therapy is narrowing, so the most pressing desire is to find an effective and safe drug. For the purpose of this article is to analyze the efficacy of temozolomide and nimotuzumab combined with postoperative chemoradiation therapy in the treatment of glioma. The adverse reaction, tolerance, stability condition and the survival rate are studied by analyzing certain clinical trials. The observation results show that the two drugs in combination of postoperative chemoradiation therapy of glioma is more curative than traditional radiation and chemotherapy treatments. For temozolomide with postoperative chemoradiation therapy of glioma, the total effective rate is 68.8% and the life extension probability is 83.05%. The total effective rate of nimotuzumab can achieve 80% above and the life extension probability is 88.38% with low side effects.